These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7749306)

  • 1. Oncogene function inhibitors of microbial origin.
    Umezawa K
    Biotechnology; 1994; 26():267-80. PubMed ID: 7749306
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunomodulators.
    Okuhara M; Kino T
    Biotechnology; 1994; 26():321-46. PubMed ID: 7749311
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypocholesterolemic agents.
    Endo A
    Biotechnology; 1994; 26():301-20. PubMed ID: 7749309
    [No Abstract]   [Full Text] [Related]  

  • 4. [Study of the novel compounds modulating signal transduction system from microbial origin].
    Imoto M
    Jpn J Antibiot; 2001 Mar; 54(3):117-25. PubMed ID: 11392682
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolation and biological activities of signal transduction inhibitors from microorganisms and plants.
    Umezawa K
    Adv Enzyme Regul; 1995; 35():43-53. PubMed ID: 7572353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors of oncogene product functions].
    Umezawa K
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):315-21. PubMed ID: 2155583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening methodologies for the discovery of novel cytotoxic antitumor agents.
    Casazza AM; Long BH
    Biotechnology; 1994; 26():281-300. PubMed ID: 7749307
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanism-based screening for the discovery of novel antifungals.
    Kirsch DR; DiDomenico BJ
    Biotechnology; 1994; 26():177-221. PubMed ID: 7749303
    [No Abstract]   [Full Text] [Related]  

  • 9. [Microbial secondary metabolites inhibiting oncogene actions].
    Uehara Y
    Seikagaku; 1990 Nov; 62(11):1374-9. PubMed ID: 2077074
    [No Abstract]   [Full Text] [Related]  

  • 10. Strategies for discovering antiviral agents from natural products.
    Rozhon E; Albin R; Schwartz J
    Biotechnology; 1994; 26():223-45. PubMed ID: 7749304
    [No Abstract]   [Full Text] [Related]  

  • 11. [Biological activity of oncogene function inhibitors isolated from microorganisms].
    Umezawa K
    Seikagaku; 1992 Mar; 64(3):160-71. PubMed ID: 1535644
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anticancer agents targeting oncogene products].
    Uehara Y
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1885-91. PubMed ID: 8379683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene activation in chemical carcinogenesis.
    Balmain A; Brown K
    Adv Cancer Res; 1988; 51():147-82. PubMed ID: 3066145
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of oncogenes in chemical carcinogenesis.
    Stowers SJ; Maronpot RR; Reynolds SH; Anderson MW
    Environ Health Perspect; 1987 Nov; 75():81-6. PubMed ID: 3319570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors.
    Corbley MJ; Cherington V; Traxler PM; Lydon NB; Roberts TM
    Int J Cancer; 1996 Jun; 66(6):753-9. PubMed ID: 8647645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and specificity of genistein as inhibitor of protein-tyrosine kinases.
    Akiyama T; Ogawara H
    Methods Enzymol; 1991; 201():362-70. PubMed ID: 1658553
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of oncogenes on the resistance to cis-diamminedichloroplatinum(II) and metallothionein gene expression.
    Yamada-Okabe T; Yamada-Okabe H; Kashima Y; Doi R
    Toxicol Appl Pharmacol; 1995 Aug; 133(2):233-8. PubMed ID: 7645018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities for pharmacological intervention in the ras pathway.
    Marshall CJ
    Ann Oncol; 1995; 6 Suppl 1():63-7. PubMed ID: 8695547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.
    Stacey DW; Roudebush M; Day R; Mosser SD; Gibbs JB; Feig LA
    Oncogene; 1991 Dec; 6(12):2297-304. PubMed ID: 1766676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipain-induced suppression of oncogene expression in H-ras-transformed NIH3T3 cells.
    Cox LR; Motz J; Troll W; Garte SJ
    Cancer Res; 1991 Sep; 51(18):4810-4. PubMed ID: 1893373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.